KeyZell Awarded for Treating Cancer with Biotechnology, Artificial Intelligence

06.28.2022 2:48 pm

Biotechnological startup Keisel has been honored at the second edition of the Isaac Perel National Research, Science and Innovation Awards organized by the European Association of Economy and Competitiveness. It identifies the competency of the entity researchers Those who do excellent work in scientific fields and who contribute to the advancement of science, better knowledge of human beings, transfer of technology and progress of humanity.

These awards recognize the research done by KeyZell in the development of artificial intelligenceAble to recommend medical professionalsIndividualized treatment against lung and breast cancer.

a more personalized medicine

Backed by an internationally renowned management and research team, Keisel enables oncologists to personalized medicine, reducing recurrence, over-medication, hospitalization time, cost of treatment, follow-up through all clinical stages Helps to take action, and above all, has a positive effect on patients’ quality of life.

In addition, it is generating a Token Generation Event (TGE) in which a Issuance of 2 Billion Tokens and 200,000 NFTs, This token issue is a risk-free investment despite the current volatility of the crypto market, as it is backed by the company’s own value, which means that this investment is not merely speculative and does not depend on market cap. With this issue, KeyZell wants to continue to advance in their project to fight cancer and operate in a safer environment, as they operate under technology.blockchain,

more praise

The startup is distinguished by attacking cancer from two fronts, research in first-line cancer treatment and use of AI technology precision medicine in oncology (Oncology Precision Systems).

The awards have also recognized the work of professionals such as Dr. Elizabeth Arrojo AlvarezMedical Director of the Medical Institute of Advanced Oncology (INMOA), who was distinguished for his professional career in research in the world of oncology, highlighting the development of a leading technology in breast cancer. Reduces the number of radiotherapy sessions From over 30 daily sessions to a single session.

See here the complete article of Pop News 24/7.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Dr Nabil Hajji

Dr Nabil Hajji

World-renowned expert in the field of oncology, recognized for establishing the mechanism underlying the resistance of classical antitumor treatments in various types of cancer, related to the epigenetic mechanism that controls apoptosis and the tumor microenvironment.

Recent news

Follow us on the networks

Subscribe to our newsletters

You will only receive notifications about new news and updates.

More news

The BME Pre Market Environment welcomes KeyZell, Pharmamel y OpenWebinars and reaches 25 companies

The Pre Market Environemnt (EpM), the BME acceleration program for the incorporation of companies into the financial markets, welcomes three new companies: KeyZell, Pharmamel and ...
Read more →
Premios EmprendeXXI de CaixaBank

KeyZell finalist in CaixaBank’s Emprende XXI Awards

KeyZell, a company dedicated to the development of artificial intelligence technology applied to cancer, has been selected as a finalist in the EmprendeXXI Awards. These ...
Read more →

KeyZell participates as a reference in biotechnology in the new edition of MAD e-Health

KeyZell has been one of the companies invited to participate on April 28th in the Madrid Capital e-Health cluster (link). The event aims to bring ...
Read more →

KeyZell awarded with the Andalucía Excelente prize, best Biotechnology company 2022.

KeyZell received the Andalucía Excelente Award as the best Biotechnology company 2022. KeyZell, awarded for its commitment to create a new future for oncology, through ...
Read more →

Comitas e-health and Keyzell implement an AI solution for the early detection of lung and breast cancer

Comitas e-health and the Andalusian company Keyzell have formalized an alliance for the development of an innovative telemedicine solution for the early diagnosis and treatment ...
Read more →

KeyZell develops the first precision medicine system to fight breast and lung cancer

The startup has developed the first oncology precision medicine system that selects “personalized treatment for each patient.”- Seguir leyendo:https://www.libertaddigital.com/ciencia-tecnologia/salud/2022-10-14/keyzell-desarrolla-el-primer-sistema-de-medicina-de-precision-para-combatir-el-cancer-de-mama-y-pulmon-6942968/   As explained by the company ...
Read more →

Fourier Intelligence, iRhythm and KeyZell are the most internationally recognized companies for revolutionizing the health sector

Health Tech World has released a compilation of the top 50 health technology innovators of 2022 who stand out for their unique innovation, outstanding technology ...
Read more →

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe”

KeyZell has been awarded as the “Most Pioneering Biotechnology Company – Europe” in the seventh edition of the “International Life Sciences Awards 2022“. This event ...
Read more →

KeyZell continues to advance in the development of its Artificial Intelligence tool

The biotech startup KeyZell has officially announced the launch of its exclusive fungible token useful to receive the service of its Artificial Intelligence system for precision medicine ...
Read more →